Matt Zuga - Jul 6, 2021 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: Chief Financial Officer
Signature: /s/ Katherine Denby, Attorney-in-Fact
Stock symbol: ABOS
Transactions as of: Jul 6, 2021
Transactions value $: $0
Form type: 4
Date filed: 7/8/2021, 06:18 PM
Previous filing: Jun 30, 2021
Next filing: Jan 21, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Conversion of derivative security		+26.2K			26.2K	Jul 6, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Series A-1 Preferred Stock	Conversion of derivative security		-15.7K	-50%		15.7K	Jul 6, 2021	Common Stock	15.7K		Direct	F1
transaction	ABOS	Series B Preferred Stock	Conversion of derivative security		-10.5K	-50%		10.5K	Jul 6, 2021	Common Stock	10.5K		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.